Current in vitro and in vivo data indicate that invasive aspergillosis due to
Invasive aspergillosis (IA) is the most common filamentous fungal infection observed in immunocompromised patients [1] [2] [3] [4] . Aspergillus fumigatus, Aspergillus flavus, Aspergillus niger, and Aspergillus terreus are the most common species causing IA [5, 6] , but most studies identify A. fumigatus or A. flavus as the etiological agent in the majority of cases. The frequency of A. terreus infections varies from 3%-12.5% [5] [6] [7] [8] [9] . Recent in vitro and in vivo studies indicate that A. terreus is distinguished from A. fumigatus, A. flavus, and A. niger as being more resistant to amphotericin B therapy [10, 11] . Further laboratory investigations also have demonstrated significantly greater in vitro and in vivo activity of new antifungal triazoles against A. terreus, with improved survival in experimental infection [11] . It is unknown whether this laboratory-documented resistance to amphotericin B or increased response to triazoles extends to the therapeutic management of human infections. Limited clinical data suggest that A. terreus infection may be associated with greater mortality than is infection with other Aspergillus species [9] . Hence, optimal therapy for this emerging mould infection remains important and uncertain.
Previous clinical reports of A. terreus infection have been limited to small case-series and case reports [9] . In addition, there are cases aggregated in larger clinical studies in which the outcomes of infection with specific Aspergillus species are not analyzed separately. The largest previous review devoted to A. terreus invasive infections was a single institution's 12-year retrospective analysis of 13 cases that occurred in 1985-1996 [9] . In the present study, we analyzed 83 recent cases of A. terreus infection (1997-2002) from 3 major US medical centers and the Voriconazole Clinical Program Database. To further understand the impact of polyene and extended-spectrum triazole therapy, we compared patient outcomes with voriconazole treatment versus patient outcomes with any other systemic antifungal treatment, principally amphotericin B. Based upon in vitro and in vivo data and preliminary clinical data, our hypothesis was that voriconazole treatment would lead to improved patient outcome for A. terreus infection, compared with the other antifungal regimens.
METHODS
Inclusion criteria and definitions. These retrospective clinical data were obtained from all cases of IA due to A. terreus treated at 3 US medical centers during a 6-year period from 1 January 1997 to 31 December 2002. Institutional review board approval was obtained at all participating institutions. Data on cases were also collected from the Voriconazole Clinical Program Database (Sandwich, United Kingdom), and some of these case data have been published elsewhere [12, 13] . The participating US medical centers were MD Anderson Cancer Center (Houston, TX), Duke University Medical Center (Durham, NC), and the Fred Hutchinson Cancer Research Center (Seattle, WA). All cases from the 3 medical centers and the Voriconazole Clinical Program Database were merged for analysis after the elimination of any duplicate cases.
Cases were determined by searching microbiology records for all cases of IA due to culture-proven A. terreus at each medical center. IA was required to be either proven IA or probable IA with culture-proven A. terreus, as defined according to the joint guidelines of the European Organization for Research and Treatment of Cancer (EORTC) and the Mycoses Study Group (MSG) of the National Institute of Allergy and Infectious Diseases [14] . Definitions were extrapolated to those patients who did not have malignancy and had not undergone hematopoietic stem cell transplantation (HSCT). Infection characteristics were determined clinically and were supported by autopsy results, if available. Day of diagnosis was defined as the day the specimen was obtained for the culture that yielded A. terreus. Primary antifungal therapy was defined as the antifungal therapy received on the day after diagnosis or on the day after the diagnostic procedure was performed, and alternative antifungal therapy was defined as alternative or additional antifungal agents administered after the primary antifungal therapy. Concurrent antifungal therapy was defined as the simultaneous administration of у2 systemic antifungal agents.
Statistical analyses. The primary outcome in our statistical models was voriconazole use, defined as receipt of voriconazole at any time after the day of diagnosis. Patients were categorized into 1 of 2 groups: those patients who received at least 1 dose of voriconazole after diagnosis, and those patients who received other systemic antifungal agents (excluding voriconazole) for treatment of their A. terreus infection. Specifically, the patients who received other triazoles or echinocandins without voriconazole were also categorized in the group that received any other antifungal. The primary outcome variable for therapeutic response was overall mortality 12 weeks after diagnosis, as assessed by multiple author review. In addition, clinical response was categorized as described elsewhere [3] . We did not compare outcomes of proven IA versus probable IA, because of previous reports indicating similar findings [15] .
To evaluate graft-versus-host disease (GVHD), we generated a dummy variable. However, only certain patients can experience GVHD-specifically, those patients who have undergone allogeneic transplantation. Thus, we generated a GVHD-transplantation term. The parameter estimate from this term reflects GVHD-transplant interaction. However, the model includes only transplant and transplant-GVHD (rather than the fully saturated transplant; GVHD; and transplant-GVHD), because only those patients who underwent transplantation are eligible to experience the exposure GVHD.
We used the Fisher's exact test to compare data for the patient groups. Our primary interest was survival; thus, we used Cox proportional hazards (PH) modeling to evaluate the impact of potential risk factors on patient outcome. Because patients who received voriconazole did not all start voriconazole therapy simultaneously, this form of analysis is susceptible to biasspecifically, a healthier patient population was selected because patients had sufficient time to receive voriconazole. Therefore, we completed 2 additional analyses. We compared survival rates for patients who received primary antifungal therapy with voriconazole versus rates for those who received the drug later in their treatment course (results are presented in this report). We also repeated the analysis by use of logistic regression. The bivariable logistic regression and Cox PH results did not substantially differ in the point estimate of effect, but differed in the widths of the 95% CIs. The logistic regression and Cox PH multivariable results were similar. The logistic regression results are not presented in this report but are available upon request. We used Stata software, version 8.1 (Stata Corporation), and SAS software, version 8.1 (SAS), for the analyses.
RESULTS

Patient characteristics.
We analyzed a total of 83 cases of IA (table 1) There were a total of 38 HSCT recipients, including 37 allogeneic HSCT recipients. The majority of the allogeneic HSCT recipients (30 [81.1%] of 37 recipients) had documented acute GVHD. Of these, 19 (63.3%) of 30 recipients had active acute GVHD on the day of diagnosis, 9 (30%) of recipients had active acute GVHD within the 14 days prior to the day of diagnosis, and 2 (6.7%) of recipients had active acute GVHD after the day of diagnosis.
A. terreus was isolated as the only pathogen in 55% of cases (table 2), but in the remaining cases, A. terreus was isolated along with other fungal pathogens. The most common pathogen isolated with A. terreus was A. fumigatus (48% of cooccurring isolates), followed by other Aspergillus species, such as A. flavus (15%), A. versicolor (7.5%), and A. nidulans (5%). In addition, 37% of the A. fumigatus isolates occurred with a third Aspergillus species, generally A. flavus. Other fungal pathogens isolated with A. terreus included with Rhizopus species (in cultures for 2 patients), and Paecilomyces species, Penicillium species, and Scedosporium apiospermum (in 1 patient each).
Antifungal therapies. We also investigated the number of patients who received concurrent combination systemic antifungal therapy for у7 days after the day of diagnosis. A total of 17 (20.7%) of 82 patients received 2 concurrent antifungal agents, and 6 (7.3%) of 82 patients received 3 concurrent antifungal agents for treatment. The most-common double-antifungal therapy was an amphotericin B lipid formulation plus caspofungin (received by 7 of 17 patients), and the second most-common combination was voriconazole plus caspofungin (received by 4 of 17). The most-common concurrent triple-antifungal regimen was an amphotericin B lipid formulation plus itraconazole plus caspofungin (received by 3 of 6 patients).
Only 2 of 83 patients received GM-CSF, and slightly more than one-half of the patients (44 of 83) received G-CSF. In addition, only 6 (7.2%) of 83 patients received granulocyte transfusions, and an equal percentage underwent surgery as adjunctive therapy for their IA.
Patient outcome. A total of 55 (66.3%) of 83 patients died (table 3) , and all except 1 of those died with active IA. Overall mortality in the voriconazole group was 55.8% (19 of 34 patients), and it was 73.4% (36 of 49 patients) in the group that received other antifungal therapy. Death in the voriconazole group occurred a mean of 100 days after diagnosis (median, 40 days; range, 6-457 days). Death in the group that received other antifungal therapy occurred a mean of 29.9 days after diagnosis (median, 11 days; range, 1-312 days). The 17 patients who received voriconazole as primary therapy had a greater overall survival rate (64.7% [11 of 17] ), compared with those patients who received voriconazole as their second or third antifungal (23.5% [ 
of 17];
). The patients who re-P p .04 ceived voriconazole as their primary antifungal therapy also had greater overall survival than those patients who received an amphotericin B formulation as their primary therapy (26.2% [ 
of 42];
). Finally, the survival rate for those patients P p .01 In the bivariable analyses (table 4), decreased mortality was observed for those patients who received voriconazole, and increased mortality was observed for those patients who underwent allogeneic transplantation and in those who experienced GVHD. In the multivariable analyses (table 5), decreased mortality was observed for those patients who received voriconazole (HR, 0.29; 95% CI, 0.15-0.56;
). The parameter P ! .01 estimates for voriconazole varied !10% in the multivariable Cox proportional hazards models, regardless of the terms included in the model. We present the full model in table 5, but more parsimonious models are available upon request.
DISCUSSION
Previous studies of A. terreus in vitro [10] and in an animal model [11] have demonstrated that A. terreus is resistant to amphotericin B but susceptible in vitro and is effectively treated in animal model infections by triazole antifungal compounds. These preclinical studies suggest that amphotericin B therapy might lead to a poor patient outcome in the treatment of A. terreus infection. However, there have been little data on management and outcome of A. terreus clinical infections. This current study, coupled with prior laboratory data [10, 11] , attempts to provide an assessment of the potential use of voriconazole in lieu of amphotericin B for the treatment of A. terreus infections.
In the multivariable analysis of 83 patients, overall survival was greater for patients who received voriconazole as a part of their antifungal therapeutic regimen, compared with patients who received other systemic antifungal compounds (largely amphotericin B formulations). Specifically, patients who received voriconazole as their primary therapy also had a greater overall survival than those who received an amphotericin B formulation as their primary antifungal therapy. The increased survival observed for those patients who received voriconazole treatment was also observed for patients who received voriconazole as an alternative antifungal therapy. This reproduces recent findings that use of primary therapy with voriconazole was more successful than initial use of amphotericin B with a later switch to another licensed agent, which demonstrates the importance of effective initial therapy for IA [16] .
The largest analysis of invasive A. terreus infections prior to our study was a single-center review [9] comparing 13 cases with 19 published reports. That review found that, for all Aspergillus species isolated, A. terreus was associated with the greatest mortality from IA and the largest percentage of cases of IA not diagnosed until postmortem examination (60%). In a review of 29 patients with IA treated with amphotericin B monotherapy (at a dosage of 1.5 mg/kg/d), all patients with isolates that had an amphotericin B MIC of !2 mg/mL survived, but 22 of 24 patients with isolates that had an amphotericin B MIC of у2 mg/mL died, including all 9 of the patients infected with A. terreus. Despite similar patient characteristics for infections with the different Aspergillus species, the lethality of the A. fumigatus infections (mortality, 63%) was lower than that of A. terreus infections (mortality, 100%) [17] . Another comparison between 20 patients with A. terreus infection and 23 patients with A. fumigatus infection revealed similar risk factors and overall therapeutic responses (15% vs. 17%). For example, only 1 of 6 patients with persistent neutropenia and A. fumigatus infection responded to therapy, while 0 of 4 with A. terreus infection responded to therapy [18] .
A. terreus infection may be a possible marker for poor clinical outcome regardless of treatment, because A. terreus infection selects for an extremely immunocompromised host. There have been several outcome analyses of IA [3, 19, 20] ; however, no study has stratified outcome according to the particular Aspergillus species to determine whether species is a critical factor. In a recent landmark study analyzing voriconazole as primary therapy for 391 patients with IA, there were 6 cases of A. terreus infection among the 110 infections in which the species were identified at baseline but were not differentiated by outcome [12] .
In our retrospective, uncontrolled study of A. terreus infection, the survival rate of patients in the voriconazole group was 47% (16 of 34 patients) compared with only 24% (14 of 49 patients) in the group who received other antifungal compounds. This result is generally lower than the overall rate of survival in the large, randomized, controlled study of patients with IA caused by all Aspergillus species, but largely caused by A. fumigatus [12] , in which survival of patients who received initial therapy with voriconazole was 70.8% (102 of 144 patients), compared with 57.9% (77 of 133) for initial therapy with amphotericin B. Although one cannot directly compare a retrospective analysis with a prospective, randomized, controlled clinical trial, this report offers some insight into the potential consideration that infection with A. terreus is a marker for a patient at a higher risk of treatment failure or death from underlying disease.
Our study has the limitations imposed on any retrospective, uncontrolled analysis, including potential patient-selection bias. We attempted to alleviate compatibility problems by combining data from a limited number of sites and a global registry with a standardized data-capture form. Although we did accumulate data from a substantial number of cases of A. terreus infection, this number is still a relatively small sample size from only 3 US centers and a centralized database and, thus, limits the power of our analyses. The majority of patients in the voriconazole group also originated from clinical trials, in which selection criteria may have excluded critically ill patients. This analysis is also vulnerable to both residual confouding (e.g., within grade of GVHD) and unmeasured confounding.
Because of the retrospective nature of the analysis and the different centers involved, the antifungal agents were not administered in a standard fashion to every patient, and, therefore, this report does not provide uniformity of treatment assessment. We chose to compare therapy with voriconazole versus therapy with any other systemic antifungal agent in our multivariable model. However, it is possible that our estimate of successful treatment in the group that received treatment with other antifungals is biased, because only 50% of the that group received only an amphotericin B product, and the other 50% received either another triazole or an echinocandin with antiAspergillus activity.
In addition, only 50% (17 of 34) of the patients who received voriconazole received it as their primary antifungal therapy. One concern would be that those patients who received voriconazole as alternative therapy were actually healthier, because they had survived long enough to receive additional therapy; this concern is similar to longstanding questions about analyzing outcomes in patients who receive oral itraconazole after initially receiving parenteral amphotericin B. However, our figures for individual mortality showed that the survival rate for patients who received voriconazole as primary therapy was greater than that of patients who received it as alternative therapy.
The management of IA today is changing; the epidemiology of IA in HSCT recipients is shifting toward late-onset disease [1] , and the treatment options for IA have, fortunately, increased in the past several years [21] . In general, the treatment of choice for IA has shifted from amphotericin B therapy [22] toward voriconazole therapy [12] . The ability to distinguish A. terreus from other Aspergillus species is important from a prognostic and therapeutic-outcome viewpoint. It is emphasized from in vitro and animal model data and previous clinical data that amphotericin B may not be a consistently effective treatment for invasive A. terreus disease. This large cohort review of 83 cases of IA caused by A. terreus is consistent with previous experimental data, because A. terreus displays some evidence of amphotericin B resistance in humans. In summary, our mul-tivariable regression analyses suggest a potential preferential treatment role for voriconazole compared with amphotericin B for this emerging deadly non-fumigatus species of Aspergillus.
